Clinical Trial Update: A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 trial to assess the safety and immunogenicity of the LTB-SA7 vaccine against Staphylococcus aureus infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Infection

Drugs mentioned

• LTB-SA7 Vaccine (LTB-SA7)

Snippet

Sponsor: LimmaTech Biologics AG | Conditions: Staphylococcus (S.) Aureus Infection | Phase 1 | Status: COMPLETED